CVS Health Corporation (CVS) Price Prediction 2026–2050

CVS Health Corporation provides health solutions in the United States. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical management capabilities; Medicare Advantage and Medicare Supplement plans; prescription drug plans (PDPs); and Medicaid health care management services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates.

The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail-order pharmacy, clinical services, disease management, medical spend management services, and pharmacy and other administrative services. It serves employers, insurance companies, unions, government employee groups, health plans, PDPs, Medicaid managed care plans, CMS, plans offered on public health insurance exchanges, and other sponsors of health benefit plans.

The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, personal care products, and other general merchandise products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, retail specialty pharmacy stores, and compounding pharmacies, as well as branches for infusion and enteral nutrition services.

The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.

CVS Health Corporation is currently priced at $104.15 with a market cap of $132.89B, ranking 114 by market size. The current price sits within a broader long-run forecast that envisions significant upside over the coming years, with near-term movement constrained by a defined 30-day range and near-term support and resistance levels.

In the near term, the stock trades with a bullish technical backdrop, supported by a 30-day range and key moving averages. The price context is complemented by a stable but evolving long-term forecast that points to meaningful upside through 2030 and beyond.

The 30-day technical frame shows room for upside alongside a defined support at $89.50 and resistance at $104.81, with a 30-day price corridor between $95.24 and $113.89. The forecast path suggests the average price may move higher over time, reflecting an improving long-term outlook.

The multi-year forecast outlines a bullish trajectory, with meaningful upside embedded in the longer horizon. In 2030 the average price is forecast at $201.59 with a min of $157.47 and a max of $274.77, and an ROI of 93.6. This supports a continued bullish stance through the decade, as the outlook projects strong gains alongside rising average prices.

By 2040, the average is forecast at $715.12 with a max of $1,090.79 and an ROI of 586.6, underscoring substantial long-term upside and continued bullish sentiment.

By 2050, the average is forecast at $1,344.80 with a max of $2,198.81 and an ROI of 1191.2, indicating exceptional longer-term upside if the forecast plays out. The forecast sequence shows bullish sentiment across the cited years, but these are estimates and not guarantees; actual results may vary. Investors should consider the uncertainty inherent in long-horizon forecasts and the possibility of downside risk.